Survival after the Onset of De Novo Donor Specific Anti-HLA Antibodies in a Consecutive Series of "Low-Risk" Renal Transplant Patients

被引：0

作者：

Everly, M. J. ^{[1
,2
]}

Rebellato, L. M. ^{[3
]}

Ozawa, M. ^{[1
,2
]}

Briley, K. P. ^{[3
]}

Catrou, P. G. ^{[3
]}

Bolin, P. ^{[3
]}

Kendrick, W. T. ^{[4
]}

Kendrick, S. A. ^{[4
]}

Haisch, C. E. ^{[3
]}

Harland, R. C. ^{[3
]}

Terasaki, P. I. ^{[1
]}

机构：

[1] Terasaki Fdn, Los Angeles, CA USA

[2] One Lambda Inc, Los Angeles, CA USA

[3] E Carolina Univ, Brody Sch Med, Greenville, NC USA

[4] Eastern Nephrol & Associates, Greenville, NC USA

来源：

AMERICAN JOURNAL OF TRANSPLANTATION | 2012年 / 12卷

关键词：

D O I：

暂无

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

180

引用

页码：80 / 80

页数：1

共 50 条

[1] Epidemiology of De Novo Donor Specific Anti-HLA Antibodies in a Consecutive Series of "Low-Risk" Renal Transplant Subjects with 5-10 Years Follow-Up
Everly, M. J.
Rebellato, L. M.
Ozawa, M.
Briley, K. P.
Catrou, P. G.
Bolin, P.
Kendrick, W. T.
Kendrick, S. A.
Haisch, C. E.
Harland, R. C.
Terasaki, P. I.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 122 - 122
[2] When Is the Best Time to Screen for De Novo Donor Specific Anti-HLA Antibodies (DSA) in Low-Risk Renal Transplant Recipients?
Everly, M.
Rebellato-deVente, L. M.
Haisch, C. E.
Ozawa, M.
Parker, K.
Briley, K. P.
Catrou, P. G.
Bolin, P.
Kendrick, W. T.
Kendrick, S. A.
Harland, R. C.
Terasaki, P., I
[J]. TRANSPLANTATION, 2012, 94 (10) : 1190 - 1190
[3] IMPACT OF EVEROLIMUS ON DE NOVO DONOR-SPECIFIC ANTI-HLA ANTIBODIES IN RENAL TRANSPLANT RECIPIENTS
Kitajima, Kumiko
Nakajima, Ichiro
Fuchinoue, Shohei
[J]. TRANSPLANT INTERNATIONAL, 2013, 26 : 245 - 245
[4] ROLE OF RITUXIMAB FOR ISOLATED DE NOVO DONOR SPECIFIC ANTI-HLA ANTIBODIES IN RENAL TRANSPLANT RECIPIENTS
Schafer, Antonia
Hadaya, Karine
Villard, Jean
Ferrari-Lacrai, Sylvie
[J]. HLA, 2020, 95 (04) : 322 - 322
[5] Role of rituximab for isolated de novo donor specific anti-HLA antibodies in renal transplant recipients
Schafer, Antonia
Ferrai-Lacraz, Sylvie
Villard, Jean
Hadaya, Karine
[J]. SWISS MEDICAL WEEKLY, 2019, : 17S - 17S
[6] The Impact of De Novo Donor Specific Anti-HLA Antibodies on the 5-Year Renal Transplant Outcome
Banasik, M.
Boratynska, M.
Koscielska-Kasprzak, K.
Zabinska, M.
Chudoba, P.
Patrzalek, D.
Halon, A.
Klinger, M.
[J]. TRANSPLANTATION, 2012, 94 (10) : 1051 - 1051
[7] De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients
Del Bello, Arnaud
Congy-Jolivet, Nicolas
Danjoux, Marie
Muscari, Fabrice
Lavayssiere, Laurence
Esposito, Laure
Cardeau-Desangles, Isabelle
Guitard, Joelle
Dorr, Gaelle
Milongo, David
Suc, Bertrand
Duffas, Jean Pierre
Alric, Laurent
Bureau, Christophe
Guilbeau-Frugier, Celine
Rostaing, Lionel
Kamar, Nassim
[J]. TRANSPLANT INTERNATIONAL, 2015, 28 (12) : 1371 - 1382
[8] An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies
Premaud, Aurelie
Filloux, Matthieu
Gatault, Philippe
Thierry, Antoine
Buchler, Matthias
Munteanu, Eliza
Marquet, Pierre
Essig, Marie
Rousseau, Annick
[J]. PLOS ONE, 2017, 12 (07):
[9] Risk Factors and Consequences of De Novo Anti-HLA Donor Specific Antibodies in Kidney Transplant Recipients: The Force Awakens
Javaid, B.
Rosen-Bronson, S.
Li, D.
Awwad, M.
Gilbert, A.
Ghasemian, S.
Verbesey, J.
Abrams, P.
Grafals, M.
Fenton, J.
Cannon, C.
Rapisura, J.
Moore, J.
Cooper, M.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 411 - 411
[10] De novo production of anti-HLA donor specific antibodies during acute renal allograft rejection
Crespo, M
Pascual, M
Tolkoff-Rubin, N
Duan, JM
Fitzpatrick, D
Collins, AB
Cosimi, AB
Colvin, R
Saidman, SL
[J]. TRANSPLANTATION, 1999, 67 (07) : S87 - S87

← 1 2 3 4 5 →